Immuno-Oncology: Functional Assays for Immune Checkpoint Inhibitors as Emerging Therapeutics

In this recent webinar, immuno-oncology experts Sofie Pattijn, chief technology officer and co-founder of ImmunXperts, a Nexelis company, and Thibaut Janss, lead scientist, ImmunXperts, answer the question, “What’s next in immuno-oncology?” Learn the latest developments in how to evaluate through in vitro bioassays — of paramount importance in the development of a successful oncology therapeutic.

“Despite after the PD-1 success, only a fraction of the patients will benefit from these treatments, this opens the pathways for other checkpoint inhibitors such as TIG and LAG-3. In order to develop those drugs, it takes a significant time from the discovery of the mechanism and bringing it to the clinic. So, translational tools such as in vitro tools to screen molecules in the development phase are an important asset to accelerate these programs.” – Sofie Pattijn

The immuno-oncology experts explain how in vitro methods mimic the tumor environment to measure therapeutic functionality, specifically showcasing assays to evaluate cellular pathways of immune cells — T cells and macrophages. Our talk highlights functional and immunogenicity assays developed in support of current and emerging therapeutics to answer:

  • Why are in vitro models essential at critical phases of development for immuno-oncology?
  • How can assays be used to support and bolster immuno-oncology development for clinical applications?

They feature the value of these in vitro assays for advanced stages of the research process for better information to progress your therapeutic to market. The technology presented in the webinar highlights a variety of clinical applications for ongoing therapeutic development as projects transition through pre-IND to clinical phases.

 “In a case study, performed in house, to show [macrophage polarization assay] can be used to study the effect of the test compound on the polarization of macrophages. It has been shown in the literature that blocking LILRB2 can prevent the differentiation of monocytes into M2-like macrophages. Moreover, it has been demonstrated that this molecule can act as a checkpoint inhibitor. Ultimately, our model can be used to study to assess test compounds on the polarization and differentiation of macrophages in vitro." –Thibaut Janss

To learn how to evaluate cellular pathways of immune cells and about functional and immunogenicity assays developed in support of current and emerging oncology therapeutics, watch the recording of the webinar.

Watch the recorded webinar